ProVerum Ltd., which offers a minimally invasive system for treating benign prostatic hyperplasia, announced the closing of an $80 million Series B equity financing round led by MVM Partners.
New investors OrbiMed and the Ireland Strategic Investment Fund also participated in the round, alongside existing investors Lightstone Ventures, Gilde Healthcare Partners, Atlantic Bridge and Enterprise Ireland, among others.
The company's ProVee System uses a nitinol stent that can help reshape an enlarged BPH prostate and alleviate lower urinary tract symptoms.
The company will use the proceeds to accelerate commercialization of its offerings.
"I'm delighted to welcome MVM, OrbiMed and ISIF to the ProVerum team," Paul Bateman, CEO of ProVerum, said in a statement. "This is an exciting time for the company as we prepare to commercialize our novel treatment for men with BPH."
Barti Software, a company offering AI-powered EHR and practice management software, announced it secured $12 million in Series A funding from Five Elms Capital.
Eye care practices use the company's software for charting with AI Scribe, messaging, scheduling patients, patient intake procedures, optical and contact lens ordering, and billing.
The funds will be used to scale its go-to-market efforts, expand its workforce, and develop new AI capabilities and workflow automation.
"Today, the eye care industry takes a massive leap forward," Colton Calandrella, CEO and cofounder of Barti, said in a statement. "This is one of the last sectors of healthcare still burdened with legacy systems. Instead of waiting a decade for modern tools to trickle in, providers using Barti now have access to the latest developments in AI designed specifically for optometrists, opticians and ophthalmologists."
Sleep.ai, formerly known as SleepScore Labs, announced its rebranding and receipt of $5.5 million in funding.
Treasure Coast Ventures led the round with participation from The Harvard Business School Alumni Angels of Greater New York, Nurture Ventures, Supermoon Capital and others.
Sleep.ai offers APIs, software development kits and a consumer app dubbed SleepScore, which enables partners to embed AI-driven sleep technology into their products.
The company's app, SleepScore, aims to help individuals sleep better using sleep coaching and its patented sonar technology.
Sleep.ai will use the funds to expand its commercialization and partnership efforts as well as scale its reach across the health, lifestyle, wellness and insurance sectors.
"This funding marks a pivotal moment where AI transforms health outcomes by transforming tens of billions of complex data points into actionable sleep intelligence," Colin Lawlor, founder and CEO of Sleep.ai, said in a statement.
"Sleep is highly complex and highly personal, with many variables impacting it. The accuracy and scale of the data are key, and the computational complexity becomes revolutionary. Our AI doesn't just analyze sleep—it interprets data in a way no human could, turning massive datasets into meaningful insights that drive better health outcomes."
